aBLA Filing Intelligence & Biosimilar Opportunity

Alhemo

Concizumab-Mtci

Hemostatic Agents

Subcutenous Injection

Alhemo is a preventive injection for people with hemophilia A or B with inhibitors, aged 12 and above. It helps reduce and prevent bleeding episodes by regulating the clotting pathway.

Approval Date

20-Dec-24

Data Exclusivity Expiry

20-Dec-28

Market Exclusivity Expiry

20-Dec-36

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

117

2028

151

2029

180

2030

213

2031

242

2032

271

Molecule profile

Details & specifications

Molecule

Concizumab-Mtci

Innovator

NOVO NORDISK INC

Dosage Form

Subcutenous Injection

Strength

60 mg/1.5 mL, 150 mg/1.5 mL and 300 mg/3 mL

Therapeutic Category

Hemostatic Agents

Usage

For routine prophylaxis to prevent bleeding episodes in hemophilia a and B

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.